跳到正文
FDA 官方药品与生物制品信息·· 6 天前AI 评分57

FDA发布肝损伤患者药代动力学指南草案并撤销2003版最终指南

Guidance Recap Podcast | Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage

AI 导读

FDA发布肝损伤患者药代动力学指南草案,并撤销2003版最终指南。草案将开展专门药代动力学研究的触发阈值从肝脏代谢或排泄占比超过20%调整为超过30%,并新增NCI标准用于癌症患者分类,但肝胆癌患者除外。FDA鼓励在2026年12月1日前通过Regulations.gov提交意见,以便在启动最终指南工作前予以考虑。

正文 · 原文

Podcast

Thank you for joining us for another episode of the Guidance Recap Podcast. The Guidance Recap Podcast provides highlights for FDA guidance documents straight from the authors. My name is Kylie Haskins, and I am the host. In today’s episode, I am excited to be talking with Martina Sahre, Regulatory Scientific Reviewer in the Office of Clinical Pharmacology, which is within the Office of Translational Sciences at CDER. She will be sharing some thoughts with us on the newly published draft guidance titled, “Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage.” Welcome, Dr. Sahre! Thank you for speaking with us today.

For listeners less familiar with this topic, why is it important to study the effect of hepatic impairment in drug development?

The liver is involved in drug elimination through various pathways, chief among them metabolism and biliary excretion. When liver disease is present, these metabolic and excretory pathways can be affected. Liver disease can also affect drug absorption, distribution, protein binding, and systemic circulation. Therefore, hepatic impairment can result in changes in a drug's pharmacokinetics or pharmacodynamics or both. As a result, patients with hepatic impairment may need different dosage recommendations or additional safety monitoring. In some cases the drug may not be recommended at all for use in patients with hepatic impairment.

Following from what I just said, characterizing the impact of hepatic impairment during clinical drug development is important to be able to provide these recommendations for use when the drug is ready to be approved. Further, when these assessments are done early in drug development, it can also facilitate the inclusion of patients with Hepatic impairment in clinical trials, which will improve the applicability of clinical trial findings and help identify ways to manage potential risks.

How has FDA’s approach to evaluating hepatic impairment evolved from the previous version of the guidance published in 2003?

The guidance includes updated recommendations on when to conduct a pharmacokinetic study in patients with hepatic impairment, how the degree of hepatic impairment is classified in patients with cancer, and it removed the stand-alone “reduced study design” category. We have also updated the considerations for derivation of dosage recommendations. The newly published draft guidance also describes how population pharmacokinetic analyses from clinical trials may be sufficient to characterize the impact of hepatic impairment when subjects with varying degrees of impairment are adequately represented and sufficient pharmacokinetic data are available. Finally, with the publication of this draft, the final guidance from 2003 is withdrawn and should no longer be used to derive recommendations.

Thank you. That is a helpful overview. Can you provide more information on some of these updates?

Certainly. First, the draft guidance updates the recommendations on when to conduct a dedicated pharmacokinetic study in patients with hepatic impairment. It recommends a study when hepatic metabolism or excretion, or both, account for more than thirty percent of the elimination of the absorbed parent drug or its active metabolites. The previous guidance used a threshold of more than twenty percent. The current guidance is now consistent with the recommendations in the final Pharmacokinetics in Patients with Impaired Renal Function guidance. A study is also recommended when small changes in drug concentrations may lead to clinically significant differences in safety or effectiveness, when the drug’s elimination pathways are not adequately characterized, when the drug is intended to treat patients with liver disease, or when it is likely to be used in patients with hepatic impairment.

Second, the draft guidance adds the National Cancer Institute Organ Dysfunction Working Group (NCI) criteria as an option to classify hepatic impairment in patients with cancer, expect for patients with hepatobiliary cancer. The Child-Pugh classification system remains the recommended method to classify hepatic impairment for  all other indications.

Third, the draft removes the separate section on reduced study designs. Instead, it presents general study design considerations all categories of hepatic impairment. One of the unique aspects of hepatic impairment is that we do not have a single continuous marker that is reflective of hepatic function, which makes it challenging to extrapolate findings from less severe to more severe groups.

For our final question, what are few key items from the draft guidance that you especially want listeners to remember?

I would highlight three key takeaways for listeners.

First, it's important to understand how hepatic impairment affects a drug’s pharmacokinetics and/or, pharmacodynamics so that appropriate dosage recommendations can be developed. It can also help determine whether to recommend avoiding use or increasing monitoring for adverse reactions in patients with hepatic impairment.

Second, the guidance recommends assessing the effect of hepatic impairment early in drug development, with the goal of facilitating the inclusion of patients with hepatic impairment in clinical trials and ensuring that trial findings are applicable to the population likely to use the drug.

Finally, while the Child-Pugh classification continues to be the recommended approach for subjects with cirrhosis, the guidance also discusses the NCI criteria for subjects with cancer and encourages assessment of other relevant markers to explore their correlation with pharmacokinetic changes.

I would like to highlight that we welcome public feedback on the draft guidance. Comments can be submitted at any time through Regulations.gov. We specifically encourage comments to be submitted by December 1, 2026, to ensure FDA can consider them before beginning work on the final guidance.

Thank you for speaking with us today about the draft guidance on Pharmacokinetics in Patients with Impaired Hepatic Function. We have learned so much from your informative discussion on the document. We would also like to thank the guidance working group for writing and publishing this guidance.

To the listeners, we hope you found this podcast useful. We encourage you to take a look at the snapshot and to read the guidance.

来源:FDA 官方药品与生物制品信息 · fda.gov